SEARCH

SEARCH BY CITATION

References

  • 1
    Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492501.
  • 2
    Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 9017.
  • 3
    Schulman S, Granqvist S, Holmström M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336: 3938.
  • 4
    Go AS, Hylek EM, Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 268592.
  • 5
    Dowlatshahi D, Butcher KS, Asdaghi N et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012; 43: 18127.
  • 6
    Flaherty ML, Adeoye O, Sekar P et al. The challenge of designing a treatment trial for warfarin-associated intracerebral hemorrhage. Stroke 2009; 40: 173842.
  • 7
    McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155: 27781.
  • 8
    Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 416.
  • 9
    McCormick D, Gurwitz JH, Goldberg RJ et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001; 161: 245863.
  • 10
    Barratt JO. The action of hirudin upon thrombin. J Physiol 1927; 64: 4753.
  • 11
    Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 257S98S.
  • 12
    Klootwijk P, Lenderink T, Meij S et al. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J 1999; 20: 110111.
  • 13
    Brandstetter H, Turk D, Hoeffken HW et al. Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics. J Mol Biol 1992; 226: 108599.
  • 14
    Antonsson KT, Bylund R, Gustafsson ND, Nilsson IO. Trypsin-like protease-inhibiting peptide derivatives, their synthesis and therapeutic use. Patent application WO9429336-A1. CA122-285553/23.
  • 15
    Eriksson BI, Agnelli G, Cohen AT et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 24906.
  • 16
    Eriksson BI, Agnelli G, Cohen AT et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study. Thromb Haemost 2003; 89: 28896.
  • 17
    Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 16918.
  • 18
    Albers GW, Diener HC, Frison L et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 6908.
  • 19
    Fiessinger JN, Huisman MV, Davidson BL et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 6819.
  • 20
    Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 171321.
  • 21
    Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Ther 2009; 86: 13946.
  • 22
    Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S98S.
  • 23
    Dahl OE, Kurth AA, Rosencher N, Noack H, Clemens A, Eriksson BI. Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacement. Int Orthop 2012; 36: 7418.
  • 24
    Hart RG, Diener HC, Yang S et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 15117.
  • 25
    Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 286470.
  • 26
    Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 113951.
  • 27
    Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 98192.
  • 28
    Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 88391.
  • 29
    Buller HR, Prins MH, Lensing AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 128797.
  • 30
    Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 234252.
  • 31
    Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 5406.
  • 32
    Prandoni P, Lensing AW, Buller HR et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 4415.
  • 33
    van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 111627.
  • 34
    Harenberg J, Marx S, Weiss C, Kramer R, Samama M, Schulman S. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 2012; 10: 14336.
  • 35
    Ogata K, Mendell-Harary J, Tachibana M et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50: 74353.
  • 36
    Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med 2011; 365: 203940.
  • 37
    Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366: 8646.
  • 38
    Radecki RP. Dabigatran: uncharted waters and potential harms. Ann Intern Med 2012; 157: 668.
  • 39
    Majeed A, Hwang H-G, Brueckmann M et al. Management and outcomes of major bleeding on dabigatran or warfarin. Circulation 2013; [Epub ahead of print].
  • 40
    Healey JS, Eikelboom J, Douketis J et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 2012; 126: 3438.
  • 41
    Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 12724.
  • 42
    Larsen TB, Rasmussen LH, Skjoth F et al. Efficacy and safety of dabigatran etexilate and warfarin in ‘real world’ patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 226473.
  • 43
    Thelus R, Villiness TC, Coster TS. Dabigatran versus warfarin among patients with atrial fibrillation: real-world post-market results. Circulation 2012; 126: A14877 (Abstract).
  • 44
    Majeed A, Meijer K, Larrazabal R et al. Mortality in vitamin K antagonists-related intracerebral bleeding treated with plasma or prothrombin complex concentrate. J Thromb Haemost 2013; 11: Abstr PB 1.45-4.
  • 45
    Schiele F, van Ryn J, Canada K et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 355462.
  • 46
    Lu G, DeGuzman FR, Hollenbach SJ et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 44651.
  • 47
    Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 67384.
  • 48
    Thorevska N, Amoateng-Adjepong Y, Sabahi R et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004; 125: 85663.
  • 49
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 50
    Hellden A, Odar-Cederlof I, Nilsson G et al. Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open 2013; 3: e002686.
  • 51
    Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002; 95: 6871.
  • 52
    Sclar DA, Robison LM, Skaer TL, Dickson WM, Kozma CM, Reeder CE. Sulfonylurea pharmacotherapy regimen adherence in a Medicaid population: influence of age, gender, and race. Diabetes Educ 1999; 5: 78.
  • 53
    Tu W, Morris AB, Li J et al. Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. Clin Pharmacol Ther 2005; 77: 189201.
  • 54
    Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013; 11: 12959.
  • 55
    Salem DN, O'Gara PT, Madias C, Pauker SG. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 593S629S.
  • 56
    Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of non-inferiority randomized controlled trials. Arch Intern Med 2012; 172: 397402.
  • 57
    Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 18756.
  • 58
    Schulman S, Kearon C, Kakkar AK et al. Extended use of dabigatran, warfarin or placebo in venous thromboembolism. N Engl J Med 2013; 368: 70918.
  • 59
    Schulman S, Kakkar AK, Schellong S et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood 2011; 118: Abstr 205.
  • 60
    Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499510.
  • 61
    Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799808.